AI-designed drug reverses biological aging markers in trial

insilico medicine developed rentosertib using generative ai for treating idiopathic pulmonary fibrosis. a trial with 42 patients showed improved lung function and collected blood samples for protein analysis. six independent ai aging clocks, developed by teams at harvard, oxford, beijing, and insilico, predicted a lower biological age for treated patients, with a drop of three to four years by week 4 and up to six years in one case. the results suggest a potential effect on biological aging, but experts warn that the small sample size and lack of testing in healthy people limit the study's conclusions.